<p>Armistice Capital LLC 在第一季度購買了 Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免費報告）的一項新股份，根據其最近向證券交易委員會（SEC）提交的 13F 文件。該基金購買了 2,988,000 股公司股票，價值約為 18,795,000 美元。在最近的報告期末，Armistice Capital LLC 持有 Trevi Therapeutics 約 2.99% 的股份。</p>
<p>其他一些機構投資者最近也買賣了 TRVI 的股票。富國銀行（Wells Fargo &amp; Company MN）在第四季度將其在 Trevi Therapeutics 的持倉增加了 40.7%。富國銀行現在擁有 33,050 股公司股票，價值 136,000 美元，此前在上個季度又購買了 9,562 股。景順（Invesco Ltd.）在第四季度將其在 Trevi Therapeutics 的持倉增加了 21.2%。景順現在擁有 23,621 股公司股票，價值 97,000 美元，此前在上個季度又購買了 4,133 股。文藝復興科技（Renaissance Technologies LLC）在第四季度將其在 Trevi Therapeutics 的持倉增加了 42.0%。文藝復興科技現在擁有 100,400 股公司股票，價值 414,000 美元，此前在上個季度又購買了 29,700 股。雷蒙德·詹姆斯金融公司（Raymond James Financial Inc.）在第四季度購買了 Trevi Therapeutics 的一項新股份，價值 49,000 美元。最後，巴克萊銀行（Barclays PLC）在第四季度將其在 Trevi Therapeutics 的持倉增加了 64.1%。巴克萊銀行現在擁有 156,267 股公司股票，價值 643,000 美元，此前在上個季度又購買了 61,035 股。目前，95.76% 的股票由對沖基金和其他機構投資者持有。</p>
<p>獲取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<p>一些分析師對該公司進行了評論。Oppenheimer 在 6 月 2 日的研究報告中重申了對 Trevi Therapeutics 股票的 “跑贏大盤” 評級。雷蒙德·詹姆斯金融公司在 8 月 8 日的研究報告中將 Trevi Therapeutics 的目標價格從 29.00 美元下調至 27.00 美元，並對該股票設定了 “強力買入” 評級。Cantor Fitzgerald 在 7 月 1 日的報告中開始覆蓋 Trevi Therapeutics。他們對該公司給予了 “增持” 評級，並設定了 25.00 美元的價格目標。Wall Street Zen 在 6 月 6 日的報告中將 Trevi Therapeutics 的評級從 “持有” 下調至 “賣出”。最後，摩根士丹利在 8 月 21 日的報告中開始覆蓋 Trevi Therapeutics。他們對該公司給予了 “增持” 評級，並設定了 18.00 美元的價格目標。兩位股票研究分析師對該股票給予了強力買入評級，八位分析師給予了買入評級。根據 MarketBeat 的數據，該股票的平均評級為 “買入”，共識目標價格為 20.11 美元。</p>
<p><strong>查看我們關於 TRVI 的最新股票報告</strong></p>
<h2>Trevi Therapeutics 股票上漲 0.7%</h2>
<p>NASDAQ TRVI 在週五開盤價為 7.26 美元。該股票的市值為 8.8412 億美元，市盈率為-17.29，貝塔值為 0.58。該公司的 50 日移動平均線為 6.92 美元，200 日移動平均線為 6.28 美元。Trevi Therapeutics, Inc.的 52 周最低價為 2.36 美元，52 周最高價為 8.78 美元。</p>
<p>Trevi Therapeutics（NASDAQ:TRVI - 獲取免費報告）在 8 月 7 日星期四發佈了其財報。該公司報告季度每股收益（EPS）為-0.09 美元，超出市場共識預期的-0.10 美元 0.01 美元。整體來看，分析師預計 Trevi Therapeutics, Inc.在當前年度將發佈-0.49 美元的每股收益。</p>
<h2>關於 Trevi Therapeutics</h2>
<p>（免費報告）</p>
<p>Trevi Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於 Haduvio 療法的開發和商業化，以治療特發性肺纖維化（IPF）和難治性慢性咳嗽（RCC）等疾病，目標是中央和外周神經系統。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Trevi Therapeutics</li>
<li>哪些華爾街分析師最準確？</li>
<li>DICKS 運動用品公司股票在財報後下跌——值得買嗎？</li>
<li>風險承受能力，適合所有人的方案並不存在</li>
<li>AI 引擎：康明斯的意外增長驅動因素</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>較小的工業公司正在經歷快速增長：原因在這裏</li>
</ul>
<p><strong>想看看其他對沖基金持有的 TRVI 嗎？</strong> 訪問 HoldingsChannel.com 以獲取 Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Trevi Therapeutics 嗎？</h2>
<p>在考慮 Trevi Therapeutics 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Trevi Therapeutics 並不在名單上。</p>
<p>雖然 Trevi Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

TRVI

<p>Armistice Capital LLC 在第一季度收購了 Trevi Therapeutics, Inc. (NASDAQ:TRVI) 的新股份，購買了 2,988,000 股，價值約為 1880 萬美元，代表約 2.99% 的持股比例。其他機構投資者也增加了對 TRVI 的持股。分析師對該股票的評級不一，普遍目標價為 20.11 美元。Trevi Therapeutics 報告的季度每股收益為（0.09 美元），超出預期。該股票目前交易價格為 7.26 美元，市值為 8.8412 億美元</p>

<p>Armistice Capital LLC purchased a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,988,000 shares of the company's stock, valued at approximately $18,795,000. Armistice Capital LLC owned approximately 2.99% of Trevi Therapeutics at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Armistice Capital LLC 在第一季度購買了 Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免費報告）的一項新股份，根據其最近向證券交易委員會（SEC）提交的 13F 文件。該基金購買了 2,988,000 股公司股票，價值約為 18,795,000 美元。在最近的報告期末，Armistice Capital LLC 持有 Trevi Therapeutics 約 2.99% 的股份。</p>
</div><p>A number of other institutional investors also recently bought and sold shares of TRVI. Wells Fargo &amp; Company MN boosted its position in Trevi Therapeutics by 40.7% during the fourth quarter. Wells Fargo &amp; Company MN now owns 33,050 shares of the company's stock worth $136,000 after purchasing an additional 9,562 shares in the last quarter. Invesco Ltd. boosted its position in Trevi Therapeutics by 21.2% during the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company's stock worth $97,000 after purchasing an additional 4,133 shares in the last quarter. Renaissance Technologies LLC boosted its position in Trevi Therapeutics by 42.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock worth $414,000 after purchasing an additional 29,700 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Trevi Therapeutics during the fourth quarter worth $49,000. Finally, Barclays PLC boosted its position in Trevi Therapeutics by 64.1% during the fourth quarter. Barclays PLC now owns 156,267 shares of the company's stock worth $643,000 after purchasing an additional 61,035 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也買賣了 TRVI 的股票。富國銀行（Wells Fargo &amp; Company MN）在第四季度將其在 Trevi Therapeutics 的持倉增加了 40.7%。富國銀行現在擁有 33,050 股公司股票，價值 136,000 美元，此前在上個季度又購買了 9,562 股。景順（Invesco Ltd.）在第四季度將其在 Trevi Therapeutics 的持倉增加了 21.2%。景順現在擁有 23,621 股公司股票，價值 97,000 美元，此前在上個季度又購買了 4,133 股。文藝復興科技（Renaissance Technologies LLC）在第四季度將其在 Trevi Therapeutics 的持倉增加了 42.0%。文藝復興科技現在擁有 100,400 股公司股票，價值 414,000 美元，此前在上個季度又購買了 29,700 股。雷蒙德·詹姆斯金融公司（Raymond James Financial Inc.）在第四季度購買了 Trevi Therapeutics 的一項新股份，價值 49,000 美元。最後，巴克萊銀行（Barclays PLC）在第四季度將其在 Trevi Therapeutics 的持倉增加了 64.1%。巴克萊銀行現在擁有 156,267 股公司股票，價值 643,000 美元，此前在上個季度又購買了 61,035 股。目前，95.76% 的股票由對沖基金和其他機構投資者持有。</p>
</div><p>Get <strong>Trevi Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of analysts have commented on the company. Oppenheimer reiterated an &#34;outperform&#34; rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Raymond James Financial decreased their target price on Trevi Therapeutics from $29.00 to $27.00 and set a &#34;strong-buy&#34; rating on the stock in a research report on Friday, August 8th. Cantor Fitzgerald started coverage on Trevi Therapeutics in a report on Tuesday, July 1st. They issued an &#34;overweight&#34; rating and a $25.00 price target for the company. Wall Street Zen cut Trevi Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Friday, June 6th. Finally, Morgan Stanley started coverage on Trevi Therapeutics in a report on Thursday, August 21st. They issued an &#34;overweight&#34; rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat, the stock has an average rating of &#34;Buy&#34; and a consensus target price of $20.11.</p>
<div class="lb-trans"><p>一些分析師對該公司進行了評論。Oppenheimer 在 6 月 2 日的研究報告中重申了對 Trevi Therapeutics 股票的 “跑贏大盤” 評級。雷蒙德·詹姆斯金融公司在 8 月 8 日的研究報告中將 Trevi Therapeutics 的目標價格從 29.00 美元下調至 27.00 美元，並對該股票設定了 “強力買入” 評級。Cantor Fitzgerald 在 7 月 1 日的報告中開始覆蓋 Trevi Therapeutics。他們對該公司給予了 “增持” 評級，並設定了 25.00 美元的價格目標。Wall Street Zen 在 6 月 6 日的報告中將 Trevi Therapeutics 的評級從 “持有” 下調至 “賣出”。最後，摩根士丹利在 8 月 21 日的報告中開始覆蓋 Trevi Therapeutics。他們對該公司給予了 “增持” 評級，並設定了 18.00 美元的價格目標。兩位股票研究分析師對該股票給予了強力買入評級，八位分析師給予了買入評級。根據 MarketBeat 的數據，該股票的平均評級為 “買入”，共識目標價格為 20.11 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on TRVI</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TRVI 的最新股票報告</strong></p>
</div><h2>Trevi Therapeutics Stock Up 0.7%</h2>
<div class="lb-trans"><h2>Trevi Therapeutics 股票上漲 0.7%</h2>
</div><p>NASDAQ TRVI opened at $7.26 on Friday. The stock has a market cap of $884.12 million, a price-to-earnings ratio of -17.29 and a beta of 0.58. The business has a fifty day moving average of $6.92 and a 200-day moving average of $6.28. Trevi Therapeutics, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $8.78.</p>
<div class="lb-trans"><p>NASDAQ TRVI 在週五開盤價為 7.26 美元。該股票的市值為 8.8412 億美元，市盈率為-17.29，貝塔值為 0.58。該公司的 50 日移動平均線為 6.92 美元，200 日移動平均線為 6.28 美元。Trevi Therapeutics, Inc.的 52 周最低價為 2.36 美元，52 周最高價為 8.78 美元。</p>
</div><p>Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. As a group, analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.</p>
<div class="lb-trans"><p>Trevi Therapeutics（NASDAQ:TRVI - 獲取免費報告）在 8 月 7 日星期四發佈了其財報。該公司報告季度每股收益（EPS）為-0.09 美元，超出市場共識預期的-0.10 美元 0.01 美元。整體來看，分析師預計 Trevi Therapeutics, Inc.在當前年度將發佈-0.49 美元的每股收益。</p>
</div><h2>About Trevi Therapeutics</h2>
<div class="lb-trans"><h2>關於 Trevi Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.</p>
<div class="lb-trans"><p>Trevi Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於 Haduvio 療法的開發和商業化，以治療特發性肺纖維化（IPF）和難治性慢性咳嗽（RCC）等疾病，目標是中央和外周神經系統。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Trevi Therapeutics</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Engines to AI: Cummins’ Surprising Growth Driver</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Smaller Industrials Names Seeing Surging Growth: Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Trevi Therapeutics</li>
<li>哪些華爾街分析師最準確？</li>
<li>DICKS 運動用品公司股票在財報後下跌——值得買嗎？</li>
<li>風險承受能力，適合所有人的方案並不存在</li>
<li>AI 引擎：康明斯的意外增長驅動因素</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>較小的工業公司正在經歷快速增長：原因在這裏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TRVI?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 TRVI 嗎？</strong> 訪問 HoldingsChannel.com 以獲取 Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TRVI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Trevi Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Trevi Therapeutics 嗎？</h2>
</div><p>Before you consider Trevi Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Trevi Therapeutics 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Trevi Therapeutics 並不在名單上。</p>
</div><p>While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Trevi Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Armistice Capital LLC 購入了 Trevi Therapeutics, Inc.的新股權 $TRVI